Cancer drug developer
is planning to issue up to 20 million shares as a result of Standard and Poor's decision to include the stock in the
The company says the offering will partially meet the anticipated demand by index funds who want to own the stock after its addition to the index.
Among other things, proceeds from the offering will be used for working capital, capital expenditures, possible future licenses and strategic investments.
Shares fell 4.6% to $50.46 Thursday.